A self-assembled DNA-nanoparticle with a targeting peptide for hypoxia-inducible gene therapy of ischemic stroke

Oh, Jungju; Lee, Jaewon; Piao, Chunxian; Jeong, Ji Hoon; Lee, Minhyung

doi:10.1039/c8bm01621f

Cited by 31 publications

(23 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 173 designed poly(lactic- co -glycolic acid) (PLGA) NPs coated with engineered CXCR4-overexpressed neural stem cell membrane for delivery of anti-edema glyburide to ischemic brain for stroke treatment. RAGE is up-regulated on neurons and glial cells in ischemic brain to induce inflammation 174 . Oh et al.…”

Section: Applicationsmentioning

confidence: 99%

See 1 more Smart Citation

Evolution of blood–brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies

Han

Jiang

2021

Acta Pharmaceutica Sinica B

168

105

View full text Add to dashboard Cite

Blood–brain barrier (BBB) strictly controls matter exchange between blood and brain, and severely limits brain penetration of systemically administered drugs, resulting in ineffective drug therapy of brain diseases. However, during the onset and progression of brain diseases, BBB alterations evolve inevitably. In this review, we focus on nanoscale brain-targeting drug delivery strategies designed based on BBB evolutions and related applications in various brain diseases including Alzheimer's disease, Parkinson's disease, epilepsy, stroke, traumatic brain injury and brain tumor. The advances on optimization of small molecules for BBB crossing and non-systemic administration routes ( e . g ., intranasal treatment) for BBB bypassing are not included in this review.

show abstract

Section: Applicationsmentioning

confidence: 99%

“…Oh et al. 174 developed RAGE-targeting peptide modified NPs for delivery of heme oxygenase-1 plasmid for ischemic stroke gene therapy. The NPs inhibited RAGE-mediated signal transduction and functioned as cytoprotective reagent to decrease inflammation, apoptosis and ROS in hypoxic cells.…”

Section: Applicationsmentioning

confidence: 99%

Evolution of blood–brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies

Han

Jiang

2021

Acta Pharmaceutica Sinica B

168

105

View full text Add to dashboard Cite

show abstract

“…After stereotactic injection in MCAO injured rats, there was a significant decrease in many pro-inflammatory markers (RAGE, iNOS, TNFα) compared to controls, and a decrease in infarct volume 1 day after injury. [342]…”

Section: (18 Of 32)mentioning

confidence: 99%

Wielding the Double‐Edged Sword of Inflammation: Building Biomaterial‐Based Strategies for Immunomodulation in Ischemic Stroke Treatment

Khait

Shoichet

2021

Adv Funct Materials

View full text Add to dashboard Cite

Stroke is a leading cause of disability with no current treatment to regenerate lost brain tissue. Innovative preclinical and clinical trials have attempted to improve stroke recovery by promoting cell survival, downregulating astrogliosis and inflammation, and improving neurogenesis and angiogenesis; however, the complexity of stroke pathophysiology raises many challenges. Previous attempts to grossly inhibit the inflammatory reaction failed to improve stroke outcomes, prompting scientists to explore selective modulation rather than unbiased inhibition. Although experimental studies involving immunomodulation are successful, strategies have largely failed in the clinic. Some of these approaches are hindered by poor delivery efficiency or cell survival, challenges that could be at least partially overcome using biomaterials. Biomaterials may enhance immunomodulatory processes by improving drug and cell delivery to the injured tissue. Furthermore, the materials themselves can support healing and may be designed to act as immunomodulators, thereby contributing to tissue regeneration and endogenous repair processes. Described here are novel biomaterial-based strategies to modulate the immune response after ischemic stroke, with an emphasis on extracellular matrix mimetics and hydrogels for local delivery of drugs and cells. Finally, a future perspective is described, highlighting the potential of these therapies to achieve clinical translation and improve patients' functional repair.

show abstract

“…[69][70][71] Another unique strategy is to deliver nucleic acids to modulate gene expression instead, such as miR-195, C3 siRNA and other plasmid vectors. [72][73][74] Free radicals had also been used as ROS scavengers among different treatment approaches to reduce I/R injury. The nitric oxide radical, amino-TEMPO, had been conjugated to a copolymer which then formed micelles with the scavengers facing inward and with PEG serving as a stealth device against RES.…”

Section: Polymer-based Carriers Micellesmentioning

confidence: 99%

<p>Nanocarriers for Stroke Therapy: Advances and Obstacles in Translating Animal Studies</p>

Alkaff¹,

Radhakrishnan²,

Nedumaran³

et al. 2020

IJN

View full text Add to dashboard Cite

The technology of drug delivery systems (DDS) has expanded into many applications, such as for treating neurological disorders. Nanoparticle DDS offer a unique strategy for targeted transport and improved outcomes of therapeutics. Stroke is likely to benefit from the emergence of this technology though clinical breakthroughs are yet to manifest. This review explores the recent advances in this field and provides insight on the trends, prospects and challenges of translating this technology to clinical application. Carriers of diverse material compositions are presented, with special focus on the surface properties and emphasis on the similarities and inconsistencies among in vivo experimental paradigms. Research attention is scattered among various nanoparticle DDS and various routes of drug administration, which expresses the lack of consistency among studies. Analysis of current literature reveals lipid-and polymer-based DDS as forerunners of DDS for stroke; however, cell membrane-derived vesicles (CMVs) possess the competitive edge due to their innate biocompatibility and superior efficacy. Conversely, inorganic and carbonbased DDS offer different functionalities as well as varied capacity for loading but suffer mainly from poor safety and general lack of investigation in this area. This review supports the existing literature by systematizing presently available data and accounting for the differences in drugs of choice, carrier types, animal models, intervention strategies and outcome parameters.

show abstract

A self-assembled DNA-nanoparticle with a targeting peptide for hypoxia-inducible gene therapy of ischemic stroke

Abstract: A self-assembled nanoparticle composed of hypoxia-specific anti-RAGE peptide (HSAP), heme oxygenase-1 plasmid (pHO1), and deoxycholate-conjugated polyethylenimine-2k (DP2k) was developed for ischemic stroke therapy.

Cited by 31 publications

References 51 publications

Evolution of blood–brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies

Evolution of blood–brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies

Wielding the Double‐Edged Sword of Inflammation: Building Biomaterial‐Based Strategies for Immunomodulation in Ischemic Stroke Treatment

<p>Nanocarriers for Stroke Therapy: Advances and Obstacles in Translating Animal Studies</p>

Contact Info

Product

Resources

About